Australian company Telix has announced that it will supply ILLUCIX for a Phase 3 study investigating the efficacy of Bayer's PBS-listed NUBEQA (darolutamide) plus androgen deprivation therapy in hormone-sensitive prostate cancer. …
Australian company to supply Bayer with Illuccix for prostate cancer study
May 9, 2023 Latest NewsBioPharmaAustralian Biotech
Latest Video
New Stories
-
Australian researchers solve decades-long mystery on Parkinson’s disease
March 14, 2025 - - Australian Biotech -
Kosi climbers about to embark on day one of 2025 challenge
March 14, 2025 - - Latest News -
Astellas cancer therapy approved for new indication in earlier prostate cancer
March 14, 2025 - - Latest News -
World-first study identifies 'Goldilocks' number of genes to include in pre-pregnancy screening
March 13, 2025 - - Latest News -
Medicines funded by Pharmac tops 50 since last year's budget boost
March 13, 2025 - - Latest News -
Australia is not alone in using rebate payments, but there are some differences
March 13, 2025 - - Latest News -
Australian company confirms the location of key clinical trial
March 13, 2025 - - Australian Biotech